ClinicalTrials.gg
TerminatedNCT01223001DuloxetineUpdated Dec 17, 2014Results posted

Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury

A Phase 2 interventional study of Duloxetine and Sugar pill in Traumatic Brain Injury and Depression, sponsored by Rehabilitation Hospital of Indiana. Terminated at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-12-17.

Sponsored by Rehabilitation Hospital of Indiana · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Most potential subjects had already been prescribed Cymbalta.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 909 studies in Brain Injuries, Traumatic with a site in United States — 212 open to participants now, 250 under way, 5 of them phase 3. Brain Injuries, Traumatic · United States.

Enrollment
576th of 650
8 · median 50
Started
1996
the only one that year
Phase 2
78 of 909
19 open now
Registered
145th of 909
by date

Among the 909 studies in Brain Injuries, Traumatic with a site in United States, this one is the 576th largest by enrollment of the 650 interventional ones that give a count, is the only one that started in 1996, is one of 78 in phase 2, and was the 145th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

212 of the 909 studies in Brain Injuries, Traumatic with a site in United States are open now. Recruiting first, the newest first:

207 more — sign in →

All 212 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Brain Injuries, Traumatic with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to compare the efficacy of duloxetine 60 mg by mouth daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury and to enhance cognitive function.

Read the detailed description

The primary objective of the study is to compare the efficacy of duloxetine 60 mg by mouth daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury and to enhance cognitive function. Research exploring the use of selective serotonin reuptake inhibitors in the treatment of post-traumatic depression generally validates this approach (Horsfield et al., 2002). However, the literature suggests that serotonin/norepinephrine reuptake inhibitors such as duloxetine may be more effective in the treatment of depression.

03

Conditions studied

  • Traumatic Brain Injury
  • Depression

Keywords

  • Depression
  • Traumatic brain injury
  • Duloxetine
  • Cymbalta
  • impaired cognitive function
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participants will be 40 men and women between the ages of 18 and 75 who provide appropriate consent and who are agreeable to study requirements
  • Diagnosed with mild to moderate traumatic brain injury as defined by an initial Mayo Traumatic Brain Injury Severity Scale
  • Have memory impairments defined by a Hopkins Verbal Learning Test delayed recall score which falls less than or equal to 1.5 standard deviation below the mean.

Exclusion criteria

Exclusion Criteria:

  • Refusal to give
  • A previous Central Nervous System illness or injury, including seizure that exhibits residual symptoms.
  • Current post-traumatic seizure disorder
  • A previous diagnosis of a psychotic disorder
  • Current or previous (in the last 6 months) treatment history for alcohol or substance dependency
  • Medications affecting noradrenergic or dopaminergic systems, alpha-adrenergic antihypertensives, antidepressant, phenobarbital, Monoamine oxidase inhibitor (MAOI), scheduled benzodiazepines, psychoactive herbal supplements (including Kava, St. John's wort), or nutritional supplements or within at least 14 days of discontinuing treatment with the above medications or supplements.
  • A known suicide risk
  • A pregnant or breastfeeding woman
  • Uncontrolled narrow-angle glaucoma
  • Serious and/or unstable medical comorbidity (e.g., AIDS, cancer, history of uncontrolled hypertension or cardiovascular disease) psychological condition, or laboratory abnormality that in the opinion of the investigator would compromise participation in the study or be likely to lead to hospitalization during the course of the study
  • Liver enzymes > 1.5 times
  • Patients with end-stage renal disease (requiring dialysis) or severe renal impairment
  • Known to duloxetine or any of the inactive ingredients
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Active comparator
    Duloxetine

    Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.

    Drug: Duloxetine

  • Placebo comparator
    Sugar pill

    Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.

    Drug: Sugar pill

Interventions

  • Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.

    Also known as: Cymbalta

  • DrugSugar pill

    Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.

    Also known as: Lactose

06

What researchers measure

Primary outcomes

  1. Hamilton Rating Scale for Depression

    To compare the efficacy of duloxetine 30 mg. PO daily to 120mg. PO daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury, utilizing the Hamilton Rating Scale for Depression (Hamilton, 1960; HAM-D) as the primary efficacy measure.

    Time frame: 9 months

Secondary outcomes

  1. Hopkins Verbal Learning Test

    To compare the effect of duloxetine vs. placebo on the recovery of memory functions of patients with traumatic brain injury, utilizing the 20-minute delayed recall score of the Hopkins Verbal Learning Test (Brandt, 1991) as the secondary efficacy measure.

    Time frame: 9 months

07

Results

Posted Dec 17, 2014
Limitations and caveats
All subjects excluded (n=6) had already been prescribed Duloxetine. Completion of the study by the remaining 4 per group was not achieved due to noncompliance.

Participant flow

Subjects recruited from in-patient and medical clinic population. All subjects suffering from traumatic brain injury and loss of cognitive function.

Participant flow — Overall Study
MilestoneDuloxetineSugar Pill
Started44
Completed00
Not completed44

Outcome measures

PrimaryHamilton Rating Scale for Depression

To compare the efficacy of duloxetine 30 mg. PO daily to 120mg. PO daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury, utilizing the Hamilton Rating Scale for Depression (Hamilton, 1960; HAM-D) as the primary efficacy measure.

Time frame:
9 months

No measurements were reported for this outcome.

SecondaryHopkins Verbal Learning Test

To compare the effect of duloxetine vs. placebo on the recovery of memory functions of patients with traumatic brain injury, utilizing the 20-minute delayed recall score of the Hopkins Verbal Learning Test (Brandt, 1991) as the secondary efficacy measure.

Time frame:
9 months

Results for this outcome have not been posted.

Adverse events

Collected over Duration of study participation per subject.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Duloxetine—0/4 (0%)0/4 (0%)
Sugar Pill—0/4 (0%)0/4 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DuloxetineSugar PillTotal
<=18 years000
Between 18 and 65 years448
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)DuloxetineSugar PillTotal
Female011
Male437
Region of Enrollment
Region of Enrollment(participants)DuloxetineSugar PillTotal
United States448
08

Study locations

1 site
  • Rehabilitation Hospital of Indiana
    Indianapolis, Indiana 46254, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 1996, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2010
First posted
Oct 18, 2010
Start
Sep 1996
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
Dec 17, 2014
Last update
Dec 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01223001
Lead sponsor
Rehabilitation Hospital of Indiana
Responsible party
Sponsor
First posted
Oct 18, 2010
Start date
Sep 1996
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Dec 17, 2014
Last update
Dec 17, 2014

Study contacts

Lance Trexler, Ph.D.
principal investigator · Rehabilitation Hospital of Indiana

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duloxetine

Start the discussion